Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation.
Two patients with disseminated mantle-cell lymphoma relapsed 24 and 13 months, respectively, after high-dose chemotherapy and autologous stem cell transplantation (autoSCT). Both patients had an HLA-identical sibling and received an allogeneic stem cell transplant (alloSCT) 32 and 18 months after autologous transplant, after conditioning with fractionated 12 Gy total body irradiation plus cyclophosphamide 120 mg/kg. They are both alive and in complete remission 24 months after transplant. Both patients have developed chronic graft-versus-host disease and their Karnofsky performance status is 90%. AlloSCT may offer a useful approach in a subgroup of patients with mantle-cell lymphoma who have relapsed after autologous transplantation.
Martínez
C
C
Institute of Hematology and Oncology, Department of Hematology, Postgraduate School of Hematology Farreras-Valenti, IDIBAPS, Hospital Clínic, University of Barcelona, Spain.
Carreras
E
E
Rovira
M
M
Urbano-Ispizua
A
A
Esteve
J
J
Perales
M
M
Fernández
F
F
Montserrat
E
E
D000971:Antineoplastic Combined Chemotherapy Protocols; D002330:Carmustine; D003520:Cyclophosphamide; D003561:Cytarabine; D005047:Etoposide; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000628:therapy*; D008297:Male; D008558:Melphalan; D008875:Middle Aged; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation
D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine